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Dear Editor,  
We read the article by Escorsell and collaborators (1) with great interest. This is the 
first randomized controlled trial comparing self-expanding metal stent (SEMS) and balloon 
tamponade in acute refractory variceal bleeding in patients with cirrhosis. Although this study 
showed that SEMS have greater efficacy in the control of bleeding and present less serious 
adverse events than does balloon tamponade, it failed to demonstrate a survival benefit.  
Even if randomized controlled trials are considered the best way to assess the impact 
of an intervention, this is probably not the case when SEMS are used to control acute 
refractory variceal bleeding for the following reasons. Firstly, blinding the therapeutic 
intervention was not possible. Secondly, the authors used patients treated with balloon 
tamponade as controls despite high rates of serious adverse events and rebleeding after 
balloon deflation. Thus, patients treated with balloon tamponade were not perfect controls. 
Thirdly, patients enrolled in this study likely differed from the average patient seen in daily 
practice. This statement is supported by the 11 exclusion criteria mentioned in the study 
design and by the low number of patients included during a 3-year period despite the many 
centers participating in the study. This is a clear limitation of this study that reduces the 
robustness of the conclusions.  
In the specific setting of acute refractory variceal bleeding, the results from 
observational studies may seem more relevant to clinical practice (2). In line with this 
comment, a recent meta-analysis (which already included Escorsell’s results) assessed the 
usefulness of SEMS in patients with cirrhosis and severe or refractory variceal bleeding (3). 
This meta-analysis showed that failure to control bleeding occurred in 18% of cases. Fewer 
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than 40% of patients treated with SEMS died after 30 days and only 12% died from recurrent 
bleeding. Even if these results are not a proof that SEMS reduce mortality, this percentage 
compares favorably to the mortality rates reported in previous studies. Furthermore, a 
significant percentage of patients had access to transjugular intrahepatic portosystemic shunt 
(26%) or to liver transplantation (10%), which underlines that SEMS can also serve as a 
bridge to a more definitive treatment.  
Overall, we believe that SEMS should be considered in patients with cirrhosis and 
uncontrolled variceal bleeding. How early SEMS should be placed during the course of acute 
variceal bleeding to achieve better control of bleeding and prevention of rebleeding before the 
development of more severe liver dysfunction remains to be assessed.  
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